Viatris
VTRS
Market cap $10.8B

9.19 USD

+0.00

0.00%

Updated Jul 30, 9:51 AM EDT

1 day

0.00%

5 days

-1.50%

1 month

2.91%

3 months

9.14%

6 months

-19.53%

Year to date

-26.01%

1 year

-24.24%

5 years

-43.72%

10 years

-83.69%

About: Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Employees: 32,000

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

58% more call options, than puts

Call options by funds: $40.9M | Put options by funds: $25.9M

9% less first-time investments, than exits

New positions opened: 110 | Existing positions closed: 121

3.14% less ownership

Funds ownership: 83.41% [Q4 2024] → 80.26% (-3.14%) [Q1 2025]

3% less funds holding

Funds holding: 1,015 [Q4 2024] → 983 (-32) [Q1 2025]

21% less repeat investments, than reductions

Existing positions increased: 293 | Existing positions reduced: 369

33% less capital invested

Capital invested by funds: $12.4B [Q4 2024] → $8.34B (-$4.05B) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 14 [Q4 2024] → 7 (-7) [Q1 2025]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$10

9%

upside

Avg. target

$10

9%

upside

High target

$10

9%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Goldman Sachs

Matt Dellatorre

9%upside

$10

Neutral

Initiated

6 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about VTRS published over the past 30 days

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Free cash flow yields show plenty of headroom for these companies to increase their dividends.

10 dividend stocks with yields up to 6.92% and plenty of cash flow for higher payouts

Zacks Investment Research

VTRS Down on Late-Stage Study Failure of Eye Disease Drug

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.

VTRS Down on Late-Stage Study Failure of Eye Disease Drug

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. VTRS on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

The pharmaceutical company says its eye inflammation treatment didn't meet its target.

Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target

Viatris eye therapy fails to meet late-stage trial goal

Viatris said on Friday that its experimental ophthalmic ointment did not meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.

Viatris eye therapy fails to meet late-stage trial goal

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

PITTSBURGH , July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study.

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

Viatris: A Contrarian Bet With Virtually No Downside

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline and global presence in key markets like the US, India, and China. The company's balance sheet is much improved, dividend yield is attractive at 5.26%, and valuation is extremely low versus sector peers. Upcoming FDA approvals and 11 key pipeline assets could drive rapid earnings growth and a major stock price re-rating toward $20 per share.

Viatris: A Contrarian Bet With Virtually No Downside

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

High-yield S&P 500 stocks can be risky, but 14 "safer" S&P 500 dividend dogs have strong free cash flow to support payouts and are attractive buys. Analyst forecasts suggest top ten S&P 500 dividend dogs could deliver 27% to 53% net gains by July 2026, with lower-than-market volatility. A market correction could make more high-yield stocks fairly priced; currently, only a select few meet the 'dogcatcher' ideal of yield from $1K invested exceeding share price.

Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

MR-141 Met Primary And All Secondary Endpoints, Demonstrating Rapid And Sustained Improvement In Near Visual Acuity Without Compromising Distance Vision Safety Profile Consistent With Previous Clinical Trials And No Treatment-Related Serious Adverse Events Reported In This Study Targeting Application To U.S. FDA In Second Half of 2025 PITTSBURGH , June 26, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive top-line results from VEGA-3, the second pivotal Phase 3 trial evaluating MR-141 (phentolamine ophthalmic solution 0.75%) in treating presbyopia. Presbyopia is the progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain, particularly in dim lighting conditions.

Viatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

PITTSBURGH , June 12, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) will report second quarter 2025 financial results on Thursday, August 7, 2025. Company executives will host a webcast at 8:30 a.m.

Viatris to Report Second Quarter 2025 Financial Results on August 7, 2025

See News Rankings

Charts implemented using Lightweight Charts™